Literature DB >> 31918323

Ultrasound-guided vacuum-assisted excisional biopsy to treat benign phyllodes tumors.

Qiu Jing Shang1, Nan Li1, Meng Ke Zhang1, Yan He1, Gang Liu2, Zhi Li Wang3.   

Abstract

PURPOSE: To evaluate the value of ultrasound (US)-guided vacuum-assisted excisional biopsy (VAB) in treating benign phyllodes tumors (PTs) of the breasts and to investigate the lesion characteristics that could affect the local recurrence rate. PATIENT AND METHODS: From December 2008 to February 2018, 93 patients with PTs diagnosed on histology underwent US-guided, 7-gauge VAB. The recurrence rate of benign PT and complications of VAB were evaluated on follow-up US every three to six months. The lesion characteristics were analyzed to identify the factors affecting the recurrence rate.
RESULTS: Of the 87 patients, local recurrence was found in 15 patients (17%) in a mean follow-up period of 35.8 months, and the rate of complete excision was 82.8% (72/87). PTs with a largest diameter less than 3.3 cm had a significantly lower recurrence rate than PTs with a largest diameter larger than 3.3 cm (P < 0.05).
CONCLUSIONS: In conclusion, US-guided VAB is an effective method to treat benign PT, especially in lesions with a diameter less than 3.3 cm.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  Excisional biopsy; Phyllodes tumor; Recurrence; Ultrasound-guided vacuum-assisted breast biopsy

Year:  2019        PMID: 31918323     DOI: 10.1016/j.breast.2019.12.008

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  2 in total

1.  Ultrasound-guided 8-Gauge vacuum-assisted excision for selected B3 breast lesions: a preliminary experience.

Authors:  Giovanna Panzironi; Giuliana Moffa; Francesca Galati; Federica Pediconi
Journal:  Radiol Med       Date:  2021-11-20       Impact factor: 3.469

2.  Margin dilemma in vacuum-assisted excisional BIOPSY to treat benign phyllodes tumors.

Authors:  Oktay Irkorucu
Journal:  Breast       Date:  2020-07-04       Impact factor: 4.380

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.